MicroRNA is a type of endogenous RNA that controls gene expression after transcription. MicroRNAs are abundant in mammalian species and target around 60% of the genes in humans and other mammals. MiRNA reverse transcription are important regulator of gene expression and potential biomarker candidates. A single miRNA can alter the expression of hundreds of genes by targeting hundreds of mRNAs. Furthermore, miRNA reverse transcription is involved in a variety of allergens, such as eosinophilic esophagitis, asthma, and others, which is expected to drive up demand for microRNA reverse transcription.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-microrna-reverse-transcription-market
Data Bridge Market Research analyses that the microRNA reverse transcription market is expected to grow at a CAGR of 16.40% in the forecast period of 2022 to 2029 and is expected to reach USD 1,108.08 million by 2029. The growing prevalence of cancer, neurological disorders, and other medical diseases and advances in genomics technology and increased R&D expenditure are boosting the microRNA reverse transcription market. Furthermore, the expanding biotechnology industry in emerging economies will provide up significant market potential.
Rising prevalence rate of cancer and neurological disorder is expected to drive the market's growth rate during the forecast period.
MicroRNA reverse transcription is employed in neurology to diagnose and prognosis Alzheimer's disease through mediated intercellular communication for biomarkers in malignancy. MicroRNA reverse transcription could also be employed in other domains, such as cardiology, to diagnose acute cardiovascular disease or heart failure faster and more accurately, and in infectious diseases to diagnose sepsis. As a result, microRNA expression profiling in human tumors correlates with cancer identification, staging, progression, and therapeutic response, boosting the market for microRNA reverse transcription.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Instruments, Kits and Reagents, Consumables), Services ( Sample Collection, Other Services), Reverse Transcription & qPCR), Application (Cancer, Kidney Disease, Neurological Disease, Cardiovascular Disease, Others), End User (Academic and Research Institutes, Biopharmaceutical Companies, Contract Research Organizations, Diagnostic Centers)
|
|
Countries Covered
|
U.S., Canada, Mexico, U.K., Germany, Italy, France, Spain, Russia, Netherland, Switzerland, Turkey, Belgium, Rest of Europe, China, India, Japan, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Israel, Egypt, South Africa, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America
|
|
Market Players Covered
|
QIAGEN (Netherlands), Merck KGaA (Germany), Illumina, Inc. (U.S.), Agilent Technologies, Inc.(U.S.), Thermo Fisher Scientific Inc. (U.S.), Takara Bio Inc (Japan), Bio-Rad Laboratories, Inc. (U.S.), MiRXES Pte Ltd. (Singapore), Abcam plc (U.K.), Quantabio (U.S.), Horizon Discovery Ltd. (U.K.), NanoString (U.S.), BioGenex (U.S.), SeqMatic LLC (U.S.),GenoSensor, LLC (U.S.), OriGene Technologies, Inc. (U.S.), System Biosciences, LLC. (U.S.), HTG Molecular Diagnostics, Inc. (U.S.), GeneCopoeia, Inc. (U.S.), New England Biolabs (U.S.),Miltenyi Biotec and/or its affiliates (U.S.),Applied Biological Materials Inc. (abm) (Canada), Nanjing Vazyme Biotech Co.,Ltd. (China)
|
|
Data Pointers Covered in Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The microRNA reverse transcription market is segmented on the basis of product type, services, method, application and end user.
- On the basis of product type, the global microRNA reverse transcription market is segmented into instruments, kits and reagents, consumables. In 2022, kits and reagents segment is expected to dominate the global microRNA reverse transcription market with 45.94% market share due to increasing applications of RT-PCR in miRNA profiling, quantitation, validation, and analysis, and rapidly increasing volumes of RT-PCR tests for COVID-19.
- On the basis of services, the global microRNA reverse transcription market is segmented into sample collection and other services. In 2022, other services segment is expected to dominate the global microRNA reverse transcription market with 65.89% market share due to increasing use of blood serum in miRNA reverse transcription, cell culture media, cell line saving, tissue culture, diagnostic reagents is driving the growth of the market.
In 2022, the other services segment is projected to hold the largest share of services segment in the microRNA reverse transcription market.
In 2022, the other services segment is anticipated to hold the largest share of global microRNA reverse transcription market due to increasing use of blood serum in miRNA reverse transcription, cell culture media, cell line saving, tissue culture, diagnostic reagents is driving the growth of the market. The other services segment is growing with a CAGR of 17.5% in the forecast period of 2022 to 2029.
- On the basis of method, the global microRNA reverse transcription market is segmented into on the basis of RT-QPCR, on the basis of kits, reagents and consumables. In 2022, reverse transcription segment in RT-QPCR segment is expected to dominate the global microRNA reverse transcription market with 63.96% market share due to increase in prevalence of diseases.
In 2022, the reverse transcription segment of method segment is anticipated to dominate the microRNA reverse transcription market.
In 2022, the reverse transcription segment of this market will dominate the microRNA reverse transcription market due to increase in prevalence of diseases. The reverse transcription segment is expected reach the highest CAGR of 17.5% in the forecast period of 2022-2029.
- On the basis of application, the global microRNA reverse transcription market is segmented into cancer, kidney disease, neurological disease, cardiovascular disease, others. In 2022, cancer segment is expected to dominate the global microRNA reverse transcription market with 58.99% market share due to increasing cancer patients.
- On the basis of end user, the global microRNA reverse transcription market is segmented into academic and research institutes, biopharmaceutical companies, contract research organizations, diagnostic centers. In 2022, academic and research institutes segment is expected to dominate the global microRNA reverse transcription market with 50.38% market share due to increase in research and development activities.
Major Players
Data Bridge Market Research recognizes the following companies as the major MicroRNA reverse transcription market players in MicroRNA reverse transcription market are QIAGEN (Netherlands), Merck KGaA (Germany), Illumina, Inc. (U.S.), Agilent Technologies, Inc.(U.S.), Thermo Fisher Scientific Inc. (U.S.), Takara Bio Inc (Japan), Bio-Rad Laboratories, Inc. (U.S.), MiRXES Pte Ltd. (Singapore), Abcam plc (U.K.).
Market Development
- In September 2021, Bio-Rad Laboratories, Inc. announced the partnership with Seegene, Inc. for the clinical development and commercialization of infectious disease molecular diagnostic products. According to the terms of the agreement, Seegene, based in Seoul, Korea, will supply diagnostic assays for use on Bio-CFX96TM Rad's Dx Real-Time PCR System in the United States, pending clinical development and FDA approval (FDA). Seegene assays provide multiplex real-time PCR detection and differentiation for up to seven targets in a single reaction, with high sensitivity and specificity. The assays take about four hours to get findings. Bio-Rad Laboratories, Inc. is a global leader in developing, manufacturing, and marketing cutting-edge products for life science research and clinical diagnostics. Our products promote the discovery process and improve healthcare by focusing on quality and customer service for over 65 years.
- In 2021, throughout the pandemic, Thermo Fisher Scientific Inc. has collaborated closely with the world's highest levels of government and healthcare institutions and the pharmaceutical and biotech industries to support research, diagnostic testing, and development efforts and production.
Regional Analysis
Geographically, the countries covered in the microRNA reverse transcription market report are U.S., Canada, Mexico, U.K., Germany, Italy, France, Spain, Russia, Netherland, Switzerland, Turkey, Belgium, Rest of Europe, China, India, Japan, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Israel, Egypt, South Africa, Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in MicroRNA reverse transcription market during the forecast period 2022 - 2029
North America will continue to dominate the MicroRNA reverse transcription market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period due to the excellent medical reimbursement facilities and rising technological advancement in this region. Clinical trials to develop innovative diagnostics and medicines are becoming more common, especially in the United States. This will propel the market's growth rate.
Asia-Pacific is estimated to be the fastest-growing region in MicroRNA reverse transcription market the forecast period 2022 - 2029
Asia-Pacific region is anticipated to grow at the highest rate during the forecast period of 2022-2029 due to the surging consumer awareness and rapid growth in population in the region. Additionally, healthcare infrastructure modernization and rising level of foreign investments in developing nations such as India and China are anticipated to enhance the market's growth rate. Proteomics and genomics developments and increased acceptance of novel tools that help researchers achieve their aims will boost the Asia Pacific region.
COVID-19 Impact Analysis
The COVID-19 pandemic had a severe influence on the healthcare market, and it is estimated to have a long-term impact on the microRNA reverse transcription industry. The virus's outbreak compelled ordinary people to deal with the infection and its control. This pandemic has severely impacted the economic sector. Due to the rising prevalence of infectious diseases, the healthcare industry is expected to undergo certain structural changes in 2022. The COVID-19 has caused major disruption to worldwide commercial and economic activity. On the bright side, the microRNA reverse transcription market is likely to improve as respective government bodies lifted the enforced lockdown restrictions. Various sectors are anticipated to rebound quickly post COVID-19 pandemic due to the wide number of applications they serve. As a result, the market is projected to stabilize in the future
For more detailed information about the microRNA reverse transcription market report, click here – https://www.databridgemarketresearch.com/reports/global-microrna-reverse-transcription-market
